Latest News from Oculox
Regulatory milestones, partnerships and clinical progress
First Italian Clinical Installations of retinaSEES-1.0 Announced
retinaSEES-1.0 is set to be installed at Studio Oculistico Dott. Vezzola in Salò and a practice in Corbetta, marking the first clinical deployments in Italy.
retinaSEES Receives CE Mark: Class IIb
retinaSEES received CE Class IIb certification in January 2026 under EU Medical Device Regulation 2017/745.
Oculox Partners with Miloftalmica for Italian Market
Oculox announces a new distribution partnership with Miloftalmica, expanding access to retinaWISE and retinaSEES across Italy's ophthalmology market.
First Italian Clinical Installations of retinaSEES-1.0 Announced
Oculox announces the upcoming installation of retinaSEES-1.0 at two ophthalmology practices in Italy: Studio Oculistico Dott. Vezzola in Salò and a second practice in Corbetta. These will be the first clinical deployments of retinaSEES in the country, enabling both sites to offer patients multi-mode laser therapy for intermediate age-related macular degeneration.
The installations are supported by Oculox's Italian distribution partner Miloftalmica, and represent a concrete first step in bringing retinaSEES into active clinical use. Oculox looks forward to working closely with both practices as part of the ongoing rollout of the device.
Studio Oculistico Dottor Vezzola, Salò
retinaSEES Receives CE Mark: Class IIb
retinaSEES received CE Class IIb certification in January 2026 under EU Medical Device Regulation 2017/745, one of the most demanding regulatory classifications for active therapeutic devices. This certification confirms that retinaSEES meets rigorous requirements for safety, performance, and clinical reliability across its intended use in the treatment of intermediate age-related macular degeneration.
The Class IIb designation reflects the device's active therapeutic nature and the level of independent conformity assessment required to bring it to market. This milestone marks a critical step in Oculox's pathway to broad clinical adoption across European healthcare institutions.
Oculox Partners with Miloftalmica for Italian Market
Oculox Technologies SA has entered a distribution agreement with Miloftalmica (www.miloftalmica.it) for the expansion of the Italian market.
The partnership is led by Miloftalmica CEO Andrea Pagani. This collaboration marks an important step in Oculox's commercial expansion, ensuring that Italian clinicians have direct access to our chromatic pupillometer and dual-mode laser therapy for dry AMD.